AngioDynamics (ANGO) Stock Price
AngioDynamics Price
Revenue has compounded at 5.7% per year over the past 19 years to 320.17 M USD. Earnings per share have grown at 12.5% per year over the last 11 years. AngioDynamics's net margin stands at -11.5%, down from -8.4% several years earlier. Analysts set a median price target of 19.50 USD, implying 26.3% above the current price. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 59% above its 52-week low.
AngioDynamics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of AngioDynamics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how AngioDynamics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing AngioDynamics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | AngioDynamics Price |
|---|---|
| 9/18/2026 | 15.44 USD |
| 9/17/2026 | 15.37 USD |
| 9/16/2026 | 15.70 USD |
| 9/15/2026 | 15.47 USD |
| 9/14/2026 | 15.51 USD |
| 9/13/2026 | 15.40 USD |
| 9/11/2026 | 15.27 USD |
| 9/10/2026 | 15.24 USD |
| 9/9/2026 | 15.32 USD |
| 9/8/2026 | 15.10 USD |
| 9/4/2026 | 15.20 USD |
| 9/3/2026 | 15.47 USD |
| 9/2/2026 | 15.62 USD |
| 9/1/2026 | 15.86 USD |
| 8/31/2026 | 16.13 USD |
| 8/30/2026 | 15.84 USD |
| 8/28/2026 | 15.82 USD |
| 8/27/2026 | 15.90 USD |
| 8/26/2026 | 15.69 USD |
| 8/25/2026 | 15.95 USD |
| 8/24/2026 | 15.58 USD |
| 8/21/2026 | 15.75 USD |
| 8/20/2026 | 15.82 USD |
| 8/19/2026 | 16.15 USD |
| 8/18/2026 | 15.98 USD |
| 8/14/2026 | 15.85 USD |
| 8/13/2026 | 15.66 USD |
| 8/12/2026 | 15.75 USD |
| 8/11/2026 | 15.75 USD |
| 8/10/2026 | 15.75 USD |
AngioDynamics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
AngioDynamics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 356.00 | 353.00 | 349.00 | 344.00 | 359.00 | 264.00 | 291.00 | 316.00 | 338.00 | 303.00 | 292.00 | 320.00 | 337.00 | 355.00 | 375.00 | 397.00 |
| 0.56 | -0.84 | -1.13 | -1.43 | 4.36 | -26.46 | 10.23 | 8.59 | 6.96 | -10.36 | -3.63 | 9.59 | 5.31 | 5.34 | 5.63 | 5.87 |
| 49.16 | 49.29 | 40.97 | 41.57 | 43.45 | 56.82 | 53.61 | 52.22 | 51.48 | 50.83 | 53.77 | 54.37 | 54.37 | 54.37 | 54.37 | 54.37 |
| 175.00 | 174.00 | 143.00 | 143.00 | 156.00 | 150.00 | 156.00 | 165.00 | 174.00 | 154.00 | 157.00 | 174.00 | 183.24 | 193.03 | 203.91 | 215.87 |
| -3.00 | 1.00 | -11.00 | -14.00 | -9.00 | -167.00 | -35.00 | -29.00 | -18.00 | -192.00 | -39.00 | -39.00 | -10.00 | -1.00 | 11.00 | 17.00 |
| -0.84 | 0.28 | -3.15 | -4.07 | -2.51 | -63.26 | -12.03 | -9.18 | -5.33 | -63.37 | -13.36 | -12.19 | -2.97 | -0.28 | 2.93 | 4.28 |
| -3.00 | -43.00 | -7.00 | 16.00 | 61.00 | -166.00 | -31.00 | -26.00 | -52.00 | -184.00 | -33.00 | -36.00 | -10.00 | -1.00 | 9.00 | 14.00 |
| -250.00 | 1,333.33 | -83.72 | -328.57 | 281.25 | -372.13 | -81.33 | -16.13 | 100.00 | 253.85 | -82.07 | 9.09 | -72.22 | -90.00 | -1,000.00 | 55.56 |
| 36.14 | 37.15 | 37.38 | 38.12 | 37.99 | 38.33 | 39.05 | 39.49 | 40.22 | 40.92 | 41.40 | 41.53 | 41.53 | 41.53 | 41.53 | 41.53 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales AngioDynamics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue AngioDynamics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare AngioDynamics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares AngioDynamics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against AngioDynamics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
AngioDynamics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
AngioDynamics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
AngioDynamics business model & stock analysis
AngioDynamics SWOT Analysis
Strengths
1. Strong market presence: AngioDynamics Inc has established a strong presence in the medical device industry, particularly in the field of minimally invasive therapeutic and diagnostic technologies.
2. Diverse product portfolio: The company offers a wide range of innovative medical devices, including vascular access products, vascular interventions, angiographic products, and oncology systems, which cater to various healthcare needs.
3. Technological advancements: AngioDynamics Inc invests heavily in research and development to ensure continuous innovation and technological advancements in its products, enabling it to stay ahead of competitors.
4. Strong financial position: The company has demonstrated strong financial performance, with steady revenue growth and healthy profit margins, providing a solid foundation for future investments and expansion.
Weaknesses
1. Dependence on a limited customer base: AngioDynamics Inc heavily relies on a few key customers, which can pose a risk if any of them significantly reduce or terminate their business relationships with the company.
2. Regulatory challenges: The medical device industry is subject to strict regulations and compliance requirements, and any non-compliance can result in product delays or recalls, impacting the company's reputation and financial performance.
3. Limited global presence: While the company has a solid market presence in the United States, its international market penetration is relatively limited, which restricts its growth potential in global markets.
4. Intense competition: AngioDynamics Inc faces intense competition from both established medical device companies and emerging startups, which may result in price pressure and difficulty in maintaining market share.
Opportunities
1. Growing demand for minimally invasive procedures: There is an increasing trend towards minimally invasive surgeries and treatments, presenting an opportunity for AngioDynamics Inc to expand its market share in this rapidly growing segment.
2. Expansion into emerging markets: The company can capitalize on the growing healthcare infrastructure in emerging markets by expanding its global presence and partnering with local distributors or healthcare providers.
3. Strategic collaborations and acquisitions: AngioDynamics Inc can explore strategic collaborations or acquisitions to enhance its product portfolio, gain access to new technologies, and expand its customer base.
4. Focus on oncology market: The rising prevalence of cancer and increasing adoption of minimally invasive treatments in oncology create opportunities for the company to develop specialized products and solutions catering to this market segment.
Threats
1. Economic downturns: Any economic downturn or financial crisis can impact healthcare spending, leading to a decrease in demand for medical devices and potentially affecting AngioDynamics Inc's sales and revenue.
2. Stringent regulatory environment: The medical device industry is subject to evolving and complex regulations, and compliance failures can lead to penalties, product recalls, or a halt in manufacturing, which may affect the company's operations and financial performance.
3. Price pressure from competitors: Intense competition within the industry can result in price wars and reduced profit margins, especially if competitors offer similar products at lower prices, posing a threat to AngioDynamics Inc's market position.
4. Technological obsolescence: Rapid advancements in technology and medical innovations could render existing products obsolete, necessitating continuous investments in research and development to stay ahead of market trends.
AngioDynamics Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
AngioDynamics Segments
AngioDynamics Revenue by Segment (1/4)
Max
Details
AngioDynamics Revenue by Segment (2/4)
Max
Details
AngioDynamics Revenue by Segment (3/4)
3 Years
5 Years
10 Years
25 Years
Max
Details
AngioDynamics Revenue by Segment (4/4)
Max
Details
AngioDynamics Revenue by Region
3 Years
5 Years
10 Years
Max
Details
AngioDynamics Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
AngioDynamics historical P/E ratio, EBIT multiple, and P/S ratio
AngioDynamics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down AngioDynamics's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in AngioDynamics's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare AngioDynamics's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
AngioDynamics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current AngioDynamics forecasts and price targets in September 2026
Analyst Price Targets 2026AngioDynamics Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 7/15/2026 | Maintained | Buy | – | |
| 7/15/2026 | Maintained | Buy | 63 | |
| 4/6/2026 | Maintained | Buy | 63 | |
| 10/3/2025 | Maintained | Buy | 63 | |
| 7/16/2025 | Maintained | Buy | – | |
| 7/16/2025 | Maintained | Buy | 63 | |
| 4/7/2025 | Maintained | Buy | – | |
| 1/10/2025 | Maintained | Buy | – | |
| 1/9/2025 | Maintained | Buy | 63 | |
| 12/10/2024 | Maintained | Buy | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
AngioDynamics Earnings Calls
AngioDynamics Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 10/1/2026 | -0.11USD | - | 80.51 MUSD | - | 2026 Q3 |
| 7/14/2026 | -0.11USD | -0.07USD | 80.24 MUSD | - | 2026 Q2 |
| 4/2/2026 | -0.11USD | -0.07USD | 76.77 MUSD | - | 2026 Q1 |
| 1/6/2026 | -0.10USD | -0.15USD | 76.43 MUSD | - | 2025 Q4 |
| 10/2/2025 | -0.14USD | -0.10USD | 76.31 MUSD | - | 2025 Q3 |
| 7/15/2025 | -0.13USD | -0.03USD | 74.26 MUSD | - | 2025 Q2 |
| 4/2/2025 | -0.13USD | 0.03USD | 74.26 MUSD | - | 2025 Q1 |
| 1/8/2025 | -0.11USD | -0.04USD | 70.57 MUSD | - | 2024 Q4 |
| 10/3/2024 | -0.15USD | -0.11USD | 67.93 MUSD | - | 2024 Q3 |
| 7/16/2024 | -0.20USD | -0.06USD | 70.85 MUSD | - | 2024 Q2 |
EESG©
Eulerpool ESG Scorecard© for the AngioDynamics stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
AngioDynamics shareholder structure
| % | Name |
|---|---|
9.22667% | |
7.42969% | |
6.40518% | |
5.33236% | |
4.77883% | |
4.41177% |
AngioDynamics Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
11.50% | SEC ↗ | |
7.70% | SEC ↗ | |
7.20% | SEC ↗ | |
7.00% | SEC ↗ | |
6.63% | SEC ↗ | |
6.10% | SEC ↗ | |
5.90% | SEC ↗ | |
5.73% | SEC ↗ | |
5.10% | SEC ↗ | |
5.10% | SEC ↗ |
AngioDynamics Executives and Management Board
13 members · avg. age 60 · 38 % women
Mr. James Clemmer (61)
President, Chief Executive Officer, Director · since 2016
5.49 M USD
Management
Mr. Stephen Trowbridge (50)
Chief Financial Officer, Executive Vice President
Ms. Laura Piccinini (55)
Senior Vice President, General Manager - Endovascular Therapies and International
Mr. Lawrence Weiss (56)
Senior Vice President, Chief Legal Officer and Corporate Secretary
Mr. Warren Nighan (55)
Senior Vice President - Global Supply Chain, Quality and Regulatory Affairs
Mr. Chad Campbell (54)
Senior Vice President, General Manager - Global Oncology and Vascular Access
Board of Directors
Mr. Howard Donnelly (64)
Independent Non-Executive Chairman of the Board
Mr. Wesley Johnson (67)
Independent Director
Ms. Jan Reed (65)
Independent Director
Ms. Eileen Auen (62)
Independent Director
Ms. Lorinda Burgess (63)
Independent Director
Ms. Karen Licitra (66)
Independent Director
AngioDynamics Supply Chain
Frequently asked questions about AngioDynamics
AngioDynamics Inc operates as a medical device company, specializing in the design, development, manufacturing, and marketing of medical, surgical, and diagnostic devices used in minimally invasive procedures. The company's business model focuses on providing innovative solutions to healthcare professionals for the treatment of vascular diseases and conditions. AngioDynamics offers a wide range of products, including ablation systems, thrombus management devices, venous access products, and peripheral vascular devices. By delivering high-quality and reliable medical devices, AngioDynamics aims to improve patient outcomes and provide value to healthcare providers.
AngioDynamics Inc is primarily active in the medical device industry.
The main competitors of AngioDynamics Inc in the market include Medtronic Inc, Boston Scientific Corporation, and Johnson & Johnson.
AngioDynamics Inc. is a leading medical technology company specializing in the development and manufacture of innovative medical devices used in minimally invasive procedures. The company was founded in 1988 and is headquartered in Latham, New York. AngioDynamics Inc. has a rich history of delivering cutting-edge solutions in areas such as vascular access, peripheral vascular disease, and oncology. With a commitment to improving patient outcomes, AngioDynamics Inc. has established itself as a trusted provider of advanced medical devices to healthcare professionals worldwide. The company's dedication to research, development, and clinical collaboration ensures continued success in the field of minimally invasive interventions.
AngioDynamics Inc has achieved several significant milestones throughout its existence. One notable accomplishment includes the development and commercialization of innovative medical devices for the treatment of peripheral vascular disease and cancer. The company has also expanded its global presence by successfully introducing its products in various international markets. Furthermore, AngioDynamics Inc has received numerous accolades and recognition for its breakthrough technologies, including the FDA approval of its groundbreaking radiofrequency ablation system. With a steadfast commitment to improving patient outcomes, AngioDynamics Inc continues to make strides in the field of medical technology and remains at the forefront of innovation.
AngioDynamics Inc is primarily present in the United States.
AngioDynamics Inc represents values of innovation, patient focus, and commitment to improving medical treatments. The company's corporate philosophy revolves around developing and delivering breakthrough medical technologies that enhance patient care and improve the quality of life. AngioDynamics is dedicated to providing innovative solutions for minimally invasive, image-guided medical procedures, with a focus on delivering superior outcomes for patients. With a strong emphasis on research and development, AngioDynamics continuously strives to advance medical technologies, ensuring patient safety, and revolutionizing the field of medical interventions.
Analysts currently set an average price target of 19.50 USD for the AngioDynamics stock (median: 19.50 USD), implying +28.1 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the AngioDynamics stock: 9 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the AngioDynamics share trades at 13.45 EUR (15.44 USD).
The AngioDynamics share (ANGO) is listed on 2 stock exchanges, including: NASDAQ (ANGO), Frankfurt (UG2.F).
AngioDynamics Inc. is a leading company in the field of minimally invasive medicine and offers innovative medical technology solutions for vascular diseases, cancer treatment, and interventional radiology. The company operates globally and distributes its products in over 90 countries. The company operates in three main business areas: Vascular Access, Peripheral Vascular, and Oncology. The Vascular Access area includes products such as port systems, catheters, and accessories used to create long-term vascular access for patients requiring repeated blood draws or infusions. The Peripheral Vascular area includes products such as atherectomy systems, thrombectomy systems, and stent systems used for the treatment of peripheral vascular diseases such as atherosclerosis and thrombosis. Oncology offers a wide range of products and systems for cancer treatment, including catheters and port systems. Another important area of AngioDynamics is interventional radiology. The company offers innovative instruments and systems for the diagnosis and treatment of diseases such as liver tumors and prostate enlargement. Products in this area include microwave-assisted tumor ablation systems, needles, catheters, and accessories. AngioDynamics is also a key player in the field of medical imaging. The company provides systems for navigation and visualization of catheters and instruments used in minimally invasive procedures. These products enable physicians to perform precise and safe procedures and offer patients faster recovery. The business model of AngioDynamics is based on the development and marketing of innovative medical solutions that improve the treatment of vascular diseases, cancer, and other diseases. The company invests in research and development to develop new products and technologies that meet the needs of physicians and patients. Additionally, the company collaborates closely with hospitals and medical facilities to ensure rapid adoption and dissemination of its products. AngioDynamics has a strong and diverse product line that enables the company to serve various markets and customers. The company offers high-quality products and solutions that are valued in medical practice worldwide. With its leadership role in research and development of minimally invasive medicine, AngioDynamics is well positioned to continue growing and maintaining its position as a leading company in the industry. Overall, AngioDynamics' business model is focused on providing innovative medical products and solutions that improve the treatment of vascular diseases, cancer, and other diseases. The company operates in multiple business areas and has a strong presence in the global market. With its extensive product line, leadership role in research and development, and close collaboration with hospitals and medical facilities, AngioDynamics is well positioned to maintain its leading role in the industry in the future.
The revenue of AngioDynamics is 320.17 M USD. This figure is based on current financial data and reflects the company's business performance.
The profit of AngioDynamics is -36.74 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of AngioDynamics is currently -17.45. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the AngioDynamics stock.
The price-to-sales ratio (P/S) of AngioDynamics is currently 2.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the AngioDynamics stock.
The Eulerpool Quality Score for AngioDynamics is 2/10.
The ISIN of AngioDynamics is US03475V1017. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of AngioDynamics is A0B9A5. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of AngioDynamics is ANGO. The ticker symbol is used to trade AngioDynamics shares on the stock exchange.
AngioDynamics paid dividends every year for the past 0 years.
AngioDynamics is assigned to the 'Health' sector.
The dividends of AngioDynamics are distributed in USD.
AngioDynamics stock
AngioDynamics Peer Group
AngioDynamics Ticker
AngioDynamics FIGI
All fundamentals and in-depth analysis of AngioDynamics
Our stock analysis for AngioDynamics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AngioDynamics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.